 VIARTIS
|
||
|
PARKINSON'S DISEASE |
||
|
|
||
|
|
PARKINSON'S DISEASE NEWS
|
|
|
LOW RESOLUTION VERSION : This is the low resolution version of Parkinson's Disease News. It is intended for those people that either : use 800x600 resolution on their monitors, or have eyesight difficulties, or have slow Internet speeds. back to HIGH RESOLUTION VERSION E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new research, news reports, new books, or ne w resources are added to Parkinson's Disease News, please double click on E-MAIL NOTIFICATION, or e-mail mail@viartis.net. No form of identity is required. E-mail addresses are not used for any other purpose.back to PARKINSON'S DISEASE home page
21st May 2013 - New research PEPPERS REDUCE THE RISK OF PARKINSON'S DISEASE Annals of Neurology [2013] May 9 [Epub ahead of print] (Nielsen SS, Franklin GM, Longstreth WT, Swanson PD, Checkoway H.) Complete abstract Nicotine has long been known to reduce the risk of Parkinson's Disease. So researchers assessed whether the risk of Parkinson's Disease is associated with the consumption of nicotine-containing vegetables edibles from the same botanical family as tobacco, Solanaceae, which includes peppers, tomatoes, and potatoes. When people with Parkinson's Disease were compared with those people that did not have it, Parkinson's Disease was found to be less likely in those people that ate more peppers, tomatoes, tomato juice, and potatoes during adulthood. An association was also found for just peppers. The likelihood of developing Parkinson's Disease was an average of 81% as likely, and in some people down to 65% as likely. The association was intensified when the nicotine concentration of the vegetables was higher. So it was nicotine that caused the effect. The potential effect largely occurred in people who had never used tobacco or who had smoked cigarettes for less than 10 years. Consumption of other vegetables was unrelated to the likelihood of developing Parkinson's Disease. For a printable version of this article click here. In order to refer to this article on its own click here.
17th May 2013 - New research PRELADENANT CLINICAL TRIAL RESULTS FOR PARKINSON'S DISEASE
Movement Disorders [2013] Apr 15 [Epub ahead of print] (S.A.Factor, K.Wolski,
D.M.Togasaki, S.Huyck, M. Cantillon, T.W.Ho, R.A.Hauser, E.Pourcher)
Complete abstract Preladenant was taken in 5mg dosages twice a day alongside L-dopa for nine months. Adverse reactions caused 14% of people to cease taking it. Adverse reactions experienced by some people were dyskinesia and constipation. Preladenant provided reductions in "off" time by between 1 hour 24 minutes and 1 hour 54 minutes. "On" time increased by between 1 hour 12 minutes and 1 hour 30 minutes. For a printable version of this article click here. In order to refer to this article on its own click here.
3rd May 2013 - New research IS GENERIC MADOPAR AS GOOD AS MADOPAR ? BMC Pharmacology and Toxicology [2013] 14 (1) : 24 (U.E.Gasser, A.Fischer, J.P.Timmermans, I.Arnet) Complete abstract Madopar was compared against seven generic versions of Madopar to see if they were as good as Madopar. Madopar, which is for the treatment of Parkinson's Disease consists of L-dopa and benserazide, which helps to prevent the breakdown of L-dopa before it is made use of. It is therefore the equivalent of Sinemet. Madopar and Sinemet differ according to which countries they are available in. For more information go to Madopar. A generic version is supposed to be interchangeable. However, generic versions are often different from the original. Every one of the seven generic versions of Madopar had one or two parameters outside the specifications of Madopar. Deviations for the active ingredients ranged from 8% more benserazide to 7% less L-dopa in two of the tablet formulations. Degradation products were measured in marked excess (26% more) in one capsule formulation, and so could pose a safety concern. Deviations for the active ingredients may go unnoticed by a new user of the generic product but may entail clinical consequences when switching over. The results therefore suggest caution when prescribing a generic version of Madopar or any other generic. For a printable version of this article click here. In order to refer to this article on its own click here.
27th April 2013 - New research HEAD INJURY AND THE RISK OF PARKINSON'S DISEASE
Movement Disorders [2013] Apr 22 [Epub ahead of print] (S.Jafari, M.Etminan,
F.Aminzadeh, A.Samii)
Complete abstract The association of Parkinson's Disease and head trauma was 1.57 (1.35-1.83), meaning that head trauma causing concussion makes Parkinson's Disease more than one and half times more likely. So although head trauma makes Parkinson's Disease more likely it is not inevitable. Further analysis of the results might have shown that very severe head injury or certain types of head injury were largely responsible for the increased likelihood of Parkinson's Disease following head trauma. For a printable version of this article click here. In order to refer to this article on its own click here.
26th April 2013 - New book HANDBOOK OF PARKINSON'S DISEASE (Fifth edition) Rajesh Pahwa (Editor), Kelly E. Lyons (Editor) Publisher's description : This volume has long prevailed as one of the leading resources on Parkinson's disease. Fully updated with practical chapters on pathology, neurochemistry, etiology, and breakthrough research, it spans every essential topic related to the identification, assessment, and treatment of PD. Reflecting the many advances that have taken place in the management of PD, this volume promotes a multidisciplinary approach to care and supplies new sections on the latest pharmacologic, surgical, and rehabilitative therapies, as well as essential diagnostic, imaging, and nonmotor management strategies. New to this edition : Early identification of premotor symptoms, Potential disease modification agents, Physical and occupational therapy Click here for more details. For more books concerning Parkinson's Disease go to Parkinson's Disease Books.
20th April 2013 - News release NEURTURIN FAILS CLINICAL TRIALS FOR PARKINSON'S DISEASE Neurturin has failed to demonstrate any effect in Parkinson's Disease. Neurturin is administered using CERE-120, which is composed of a harmless adeno-associated virus (AAV) vector, which carries the gene for neurturin. Neurturin, which is naturally occurring, is known to repair damaged and dopamine-secreting neurons by restoring their function. Neurturin is a member of the same protein family as GDNF. CERE-120 is delivered by injection in to the brain. CERE-120 is produced by Ceregene Inc. The clinical trial did not demonstrate statistically significant efficacy. Yet, following surgery, there was a marked placebo effect in those people being tested and even those not being tested, as there often is after surgical trials. The clinical trial was supported by the Michael J.Fox Foundation. The results suggest that it is unclear if Ceregene will move forward with the development of CERE-120 as a viable treatment for people with Parkinson’s Disease. For more information go to the News release. For a printable version of this article click here. In order to refer to this article on its own click here.
18th April 2013 - New research BRAIN CELL LOSS IN PARKINSON'S DISEASE JAMA Neurology [2013] 70 (2) : 241-247 (D.A.Ziegler, J.S.Wonderlick, P.Ashourian, L.A.Hansen, J.C.Young, A.J. Murphy, C.K.Koppuzha, J.H.Growdon, S.Corkin) Complete abstract For many years it has been widely claimed that, in Parkinson's Disease, there is a huge loss of the dopaminergic neurons (the brain cells that produce dopamine). It is often claimed that this cell loss is the primary cause of Parkinson's Disease. However, not a single study had ever actually shown that there was massive cell loss in Parkinson's Disease. It has also been assumed that loss of the dopaminergic neurons that can cause Parkinson's Disease precedes the loss of cholinergic neurons, which can lead to dementia, as is common in later Parkinson's Disease. However, the results of a study assessing this theory did not support what had often been claimed. Researchers assessed the volume of the brain in the area in which dopaminergic neurons are common. They found that the volume of the brain in this area was decreased in people with mild Parkinson's Disease but not in people that did not have Parkinson's Disease. However, in more severe Parkinson's Disease there was no greater loss of volume of the brain in the area affected by Parkinson's Disease as there would have been if the severity of Parkinson's Disease was due to cell loss. Research has always instead been consistent with a major reduction in cell activity rather than an actual loss of the cells involved in Parkinson's Disease. For a printable version of this article click here. In order to refer to this article on its own click here.
16th April 2013 - New book DEFYING DEMENTIA Kevin Davies Publisher's description : As we get older there are few things more frightening than forgetting someone's name or where you left your house keys. For millions of us the first few times this happens we fear we're experiencing the onset of dementia. Recognizing the symptoms can lead to an early diagnosis which can mean better treatment options, a longer, better life and a change to take steps to slow or reduce the symptoms of dementia. There are many drugs and treatments the patient needs to retrain parts of their brain that have been damaged. You can DEFY it by learning the symptoms, getting diagnosed early, and getting treatment quickly. Diagnosis only takes 10 minutes. Ten minutes is all that stands between you and knowing if your lapse of memory is fatigue, a vitamin B deficiency, some other curable disease, or depression. Click here for more details.
13th April 2013 - New review TECHNOLOGICAL DEVICES FOR PARKINSON'S DISEASE (Part 1) In recent years technological devices have started being used to try to improve or aid people with Parkinson's Disease without the necessity for drugs or surgery : LIGHT THERAPY consists of daily exposure to daylight, brighter artificial light, or to specific wavelengths of light. Light suppresses melatonin formation, which lowers dopamine activity. For more information go to Light therapy. LASER DEVICES, including laser lights attached to canes, handheld devices or the Parkinson walkers. They display a beam of light on the ground, providing a target to step over to help overcome freezing episodes. For more information go to Laser cane and Laser Walker. FUNCTIONAL ELECTRICAL STIMULATION is the use of electrical impulses to stimulate weak or paralysed muscles. For more information go to Functional electrical stimulation. FOCUSED ULTRASOUND uses multiple intersecting beams of ultrasound energy are focused with a high degree of precision and accuracy on the target. For more information go to Focused Ultrasound. MAGNETIC THERAPY involves the use of an extremely low-level electromagnetic field applied by a specially designed device, the Magnesphere. Helmholtz coils immerse the entire patient in a low strength electromagnetic field. For more information go to Magnetic therapy. For a printable version of this article click here. In order to refer to this article on its own click here.
6th April 2013 - New research ISTRADEFYLLINE CLINICAL TRIAL RESULTS FOR PARKINSON'S DISEASE
Movement Disorders [2013] Mar 11 [Epub ahead of print] (Y.Mizuno, T.Kondo, the
Japanese Istradefylline Study Group)
Complete abstract After a 12 week clinical trial using 20mg or 40mg istradefylline the change in daily OFF time was significantly reduced with 20mg per day and 40 mg per day. The daily OFF time was over 40 minutes less. However, the most common adverse event was dyskinesia, which occurred more commonly when taking istradefylline than when taking a placebo. For a printable version of this article click here. In order to refer to this article on its own click here.
5th April 2013 - New book AVOID 1-CLICK SHOPPING IF YOU HAVE PARKINSON'S C. Michael Beetner Publisher's description : Being diagnosed with Parkinson’s disease is always a very scary experience. What patients need is a guide that explains, in simple terms, what to expect and how to deal with the disease. The author, who was diagnosed in 1994, quickly became an advocate and worker in the Central Ohio Parkinson’s Society (COPS). COPS has always had a monthly newsletter giving him an opportunity to write monthly on the various aspects of the disease. This book is a compilation of the best columns over many years. All are written with a dry (and often off-beat) sense of humor. There are chapters on his deep brain surgery for Parkinson’s, treatment errors he has seen, and everything else from loosing the right to drive and Sex vs. PD. Click here for more details. For more books concerning Parkinson's Disease go to Parkinson's Disease Books.
1st April 2013 - New research INHALED DOPAMINE AGONIST CLINICAL TRIAL RESULTS
Acta Neurologica Scandinavica [2013] Mar 26 [Epub ahead of print] (K.A.Grosset,
N.Malek, F.Morgan, D.G. Grosset)
Complete abstract Inhaled doses were gradually increased until efficacy was reached and given to patients when they were in an 'off' state. When it was inhaled, apomorphine was rapidly absorbed, within 2 to 7 minutes. This enabled a reversal from the 'off' state, in just 10 minutes. In contrast many people with Parkinson's Disease have to wait 30 to 60 minutes for their Parkinson's Disease drugs to have effect. Therefore, speed of effect appears to be its greatest benefit. Adverse effects did not differ between those taking inhaled apomorphine and those taking a placebo. For a printable version of this article click here. In order to refer to this article on its own click here.
30th March 2013 - New book PARKINSON'S TREATMENT : 10 SECRETS TO A HAPPIER LIFE Michael S.Okun MD Publisher's description : I never assume a sufferer or family member is aware of the “secrets” that may lead to hope and to a happier life. We must share these secrets, and this is the purpose of this book. Each chapter of this book reveals an important secret, and with each secret I will explain the insight, the rationale, the empiricism, and the science behind it. In each chapter I will also try to reveal a little more about myself, and a lot more about the patients and talented clinicians who gifted the Parkinson's secrets. These patients planted the seed of faith. They learned to grow hope, and they discovered the core values necessary to achieve happiness despite the chronic illness of Parkinson's disease. Click here for more details. For more books concerning Parkinson's Disease go to Parkinson's Disease Books.
24th March 2103 - News release NEW L-DOPA PRODUCT EXCEEDS THE EFFECT OF STALEVO A new L-dopa product, which is presently called ODM-101, significantly decreased daily OFF-time without increasing ON-time with troublesome dyskinesias when compared to Stalevo, which is a standard medication in advanced Parkinson's Disease when people experience end-of-dose wearing off symptoms using L-dopa. Stalevo contains three active substances in one tablet : L-dopa, plus carbidopa and entacapone, both of which help to maintain L-dopa levels. For more information go to Stalevo. ODM-101 has the same components as Stalevo but has a higher and fixed amount of carbidopa (either 65mg or 105 mg) regardless of the L-dopa dosage. As it made by the same manufacturers it is effectively an improved form of Stalevo. People with Parkinson's Disease were given two forms of ODM-101 with two different amounts of carbidopa : ODM-101/65mg and ODM-101/105mg. Both of them reduced daily OFF-time more than Stalevo. ODM-101/105mg was marginally better than ODM-101/65mg. Similarly, both ODM-101 combinations increased the ON-time without troublesome dyskinesia significantly more than Stalevo. There were no significant differences between the treatments in ON-time with troublesome dyskinesia or in UPDRS II and III symptom scores. Overall, tolerability and safety of ODM-101 was comparable to that of Stalevo. For more information go to the News release. For a printable version of this article click here. In order to refer to this article on its own click here.
23rd March 2013 - New research PIMAVANSERIN CLINICAL TRIAL RESULTS IN PARKINSON'S DISEASE In a phase III clinical trial, Pimavanserin had effect in the treatment of psychosis in Parkinson's Disease. Parkinson’s Disease Psychosis usually consists of visual hallucinations and delusions. It is normally due to Parkinson's Disease drugs not Parkinson's Disease. It eventually occurs in up to 60% of people with Parkinson's Disease. Pimavanserin is an antagonist of serotonin 5-HT2A receptors. It is taken orally as a tablet once-a-day. Patients took 40mg Pimavanserin for only six weeks. So its long term effects have not been assessed. The adverse events were little different from those found in people taking a placebo. Pimavanserin demonstrated significant antipsychotic efficacy and significant improvements in all secondary efficacy measures. Statistically significant benefits were also observed in exploratory measures of nighttime sleep, daytime wakefulness, and caregiver burden. For more information go to the News release. For a printable version of this article click here. In order to refer to this article on its own click here.
14th March 2013 - New research BEING OVERWEIGHT IS MORE PREVALENT IN PARKINSON'S DISEASE Arquivos de Neuropsiquiatra [2012] 70 (11) : 843-846 (H.Morales-Briceño, A.Cervantes-Arriaga, M.Rodríguez-Violante, J.Calleja-Castillo, T.Corona) Complete abstract Underweight and malnutrition are well documented in Parkinson's Disease (PD), while being overweight has been less reported. Researchers carried out a study comparing the weight and height of people with and without Parkinson's Disease. In those people with Parkinson's Disease only 1% were underweight, 33% were within the normal range, 47%% were overweight, and 19% were obese. Being normal weight and overweight were more prevalent in those people who had Parkinson's Disease when compared to those people who did not. Being obese and, even moreso, being underweight were more common in those people who did not have Parkinsons' Disease. For a printable version of this article click here. In order to refer to this article on its own click here.
5th March 2013 - News release CLINICAL TRIAL OF SUBCUTANEOUS L-DOPA FOR PARKINSON'S DISEASE NeuroDerm announced today the results of a Phase I safety and pharmacokinetic trial of ND0612. ND0612 is a novel drug formulation for the treatment of Parkinson’s Disease. NeuroDerm is a pharmaceutical company that specializes in the development of novel dermal delivery routes for CNS drugs. ND0612 is a combination of L-dopa and carbidopa, as is Sinemet, but it is a liquid formula administered continuously sub-cutaneously (via the skin) through a patch pump. It is designed to provide steady L-dopa blood levels for the reduction of motor complications in Parkinson’s Disease. In this double-blind, placebo controlled, dose-escalation trial in young, healthy volunteers, ND0612 was shown to be safe and tolerable in all of the tested doses. Clinically meaningful L-dopa concentrations were reached. For the first time in humans, steady state L-dopa concentrations were maintained in a practical manner both day and night, thereby enabling more even levels of L-dopa than oral forms of L-dopa. The full results of this study will be presented at a future scientific meeting. For more information go to the News release For a printable version of this article click here. In order to refer to this article on its own click here.
3rd March 2013 - New survey SURVEY OF THE CAUSES OF PARKINSON'S DISEASE Parkinson's Database are conducting a survey of the causes of Parkinson's Disease. They believe that the mass accumulation of data for Physicians and Researchers will provide better treatments and faster diagnosis. They want to accumulate as much pertinent data on Parkinson's Disease and related diseases as possible. They believe that this data needs to come from the patients themselves in order to paint a much clearer picture of this disease for researchers. They do not want personal information. They believe that they will receive a much wider and more honest responses by providing anonymity. For more information go to Parkinson's Database For those interested in participating the survey is linked to on the left hand side of the page.
18th February 2013 - News release COGANE FAILS CLINICAL TRIALS FOR PARKINSON'S DISEASE Phytopharm announced the results of the Phase II, randomised, double blind, placebo controlled, dose-ranging trial of Cogane in unmedicated patients with early-stage Parkinson’s Disease. Cogane was found to have no beneficial effects at all on Parkinson's Disease symptoms. For more information go to the News releaseCogane, which can be taken orally, readily crosses the blood-brain barrier and has been shown to stimulate the release of GDNF. GDNF can indirectly stimulate the formation of dopamine, the substance whose insufficiency causes Parkinson's Disease. However, GDNF deficiency has never been shown to be the cause of Parkinson's Disease. Previous studies claiming efficacy for Cogane in Parkinson's Disease were only carried out in Macaque monkeys who did not actually have Parkinson's Disease. For a printable version of this article click here. In order to refer to this article on its own click here.
15th February 2013 - New research DBS IS EFFECTIVE IN EARLIER PARKINSON'S DISEASE New England Journal of Medicine [2013] 368 (7) : 610-622 (Schuepbach WM, Rau J, Knudsen K, Volkmann J, Krack P, Timmermann L, Hälbig TD, Hesekamp H, Navarro SM, Meier N, Falk D, Mehdorn M, Paschen S, Maarouf M, Barbe MT, Fink GR, Kupsch A, Gruber D, Schneider GH, Seigneuret E, Kistner A, Chaynes P, Ory-Magne F, Brefel Courbon C, Vesper J, Schnitzler A, Wojtecki L, Houeto JL, Bataille B, Maltête D, Damier P, Raoul S, Sixel-Doering F, Hellwig D, Gharabaghi A, Krüger R, Pinsker MO, Amtage F, Régis JM, Witjas T, Thobois S, Mertens P, Kloss M, Hartmann A, Oertel WH, Post B, Speelman H, Agid Y, Schade-Brittinger C, Deuschl G; EARLYSTIM Study Group) Complete abstractResearchers assessed whether it would be suitable to use Subthalamic stimulation at an earlier stage of Parkinson's Disease. Subthalamic stimulation, which is referred to as DBS (Deep Brain Stimulation), involves the use of electrodes that are implanted into the brain and connected to a small electrical device called a pulse generator that can be externally programmed. DBS can reduce the need for L-dopa and related drugs, which in turn decreases the involuntary movements called dyskinesias that are a common side effect of L-dopa. For more information go to Deep brain stimulation In a two year clinical trial people with Parkinson's Disease and early motor complications (with an average age of 52 and a mean duration of Parkinson's Disease of 7.5 years) underwent neurostimulation plus medical therapy or only medical therapy alone. The primary end point was quality of life, as assessed with the use of the Parkinson's Disease Questionnaire (PDQ-39) with scores ranging from 0 to 100 and higher scores indicating worse function. For the primary outcome of quality of life, the mean score for the neurostimulation group improved by 7.8 points, and that for the medical-therapy group worsened by 0.2 points. Neurostimulation was superior to medical therapy with respect to motor disability, activities of daily living, L-dopa induced motor complications, and time with good mobility and no dyskinesia. Serious adverse events occurred in 54% of the people in the neurostimulation group and in 44% of those in the medical therapy group. Serious adverse events related to surgical implantation or the neurostimulation device occurred in 17% of people. For a printable version of this article click here. In order to refer to this article on its own click here.
14th February 2013 - New research MOLECULAR HYDROGEN WATER FOR PARKINSON'S DISEASE Movement Disorders [2013] Feb 11 (A.Yoritaka, M.Takanashi, M.Hirayama, T.Nakahara, S.Ohta, N.Hattori, D.Weintraub, K.Papay, A.Siderowf) Complete abstract Oxidative stress is involved in the progression of Parkinson's Disease. Recent studies have confirmed that molecular hydrogen (H2) functions as a highly effective antioxidant in cultured cells and animals. Drinking molecular hydrogen dissolved water had reduced oxidative stress and improved Parkinson's Disease features in animals. A pilot study was carried out in people with Parkinson's Disease who were taking L-dopa. Each person drank either a litre a day of molecular hydrogen water or only water (without the molecular hydrogen). Symptom scores improved in those people who drank molecular hydrogen water and worsened in those people who only drank normal water. The drinking of molecular hydrogen water was found to safe and well tolerated. It would therefore be an easy means of delaying or reducing symptoms. A larger clinical trial is intended. For a printable version of this article click here. In order to refer to this article on its own click here.
7th February 2013 - News release POSITIVE RESULTS CLAIMED FOR STEM CELLS IN PARKINSON'S DISEASE International Stem Cell Corporation have claimed positive results from its pre-clinical study using stem cells in the treatment of Parkinson's Disease. The primary goal of the study was to demonstrate the benefits of neuronal cells derived from human stem cells. The neuronal cells were derived from human parthenogenetic stem cells, which are not obtained via reproduction. They can become neurons when they are implanted in to the brain. The study was carried out for 12 weeks on rats who did not actually have Parkinson's Disease. The rats were instead given 6-OHDA (6-Hydroxydopamine), which is a toxin used to kill dopaminergic neurons (the cells involved in Parkinson's Disease). The actual results for the study have not been disclosed. It has only been stated that "signs of improvement in rotational behavior of these animals were clearly observed." For more information go to the News release Although it was claimed for many years that stem cells could rid Parkinson's Disease, stem cell operations have not fulfilled those claims. It was widely believed that stem cell operations were essential because there was a massive loss of cells involved in Parkinson's Disease. However, no study has ever demonstrated massive cell loss in Parkinson's Disease. For a printable version of this article click here. In order to refer to this article on its own click here.
6th February 2013 - New book SO I'VE GOT PARKINSON'S DISEASE Terry Rummins Publisher's description : Terry Rummins was diagnosed with Parkinson's 10 years ago. So, I've Got Parkinson's Disease is her story and covers her diagnosis and the progression of the condition - from the first warning tremors in her right hand to her day-to-day life now. Terry has written this book in the hope that describing her experience will benefit others who have been diagnosed with Parkinson's and to help them understand their expectations of how the condition may affect them. This is a candid story, told with humour and contains a positive message for those recently diagnosed and those close to them. It is also for anyone interested in what happens when life presents an unpleasant surprise. Click here for more details. For more books concerning Parkinson's Disease go to Parkinson's Disease Books.
29th January 2013 - New research USING CELL PHONES TO MONITOR PARKINSON'S DISEASE IEEE Transactions on Biomedical Engineering (submitted) [2013] (A.Tsanas, M.A.Little, P.E.McSharry, L.O. Ramig) Complete abstract Dysphonia is an impairment in the ability to produce vocal sounds that can occur in Parkinson's Disease. A wide range of dysphonia measures have been used to predict Parkinson's Disease severity using speech signals. Researchers demonstrated that this method can match standard methods of diagnosing Parkinson's Disease. Telephone monitoring of Parkinson’s Disease has attracted interest as a potential means of assessing this. Purpose built devices have been developed that record various signals that can be associated with symptom severity, as quantified on standard Parkinson's Disease scores such as the Unified Parkinson’s Disease Rating Scale (UPDRS). Previous studies have demonstrated replication of UPDRS scores to within less than 2 points of a clinical raters’ assessment of symptom severity, using solely high-quality speech signals. This study investigated using the cellular mobile telephone networks for Parkinson's Disease monitoring. The Parkinson's Disease (UPDRS) symptom score could be estimated to within about 3.5 points difference from the clinicians’ assessment, which is useful because even different clinicians vary by as much as 4 to 5 points. This provides evidence that the phone network is adequate for inexpensive, mass-scale Parkinson's Disease symptom monitoring. For a printable version of this article click here. In order to refer to this article on its own click here.
28th January 2013 - New book THE ESSENTIAL DYSPHAGIA HANDBOOK : REAL LIFE DECISIONS, MINDMAPPING AND MORE Dr Claire Langdon, Karen Jardine, Dr Julie Cichero Dysphagia is difficulty in swallowing and occurs in many people with Parkinson's Disease. Publisher's description : The goal of this book is to fill a gap that currently exists between the theoretical learning that takes place in the university setting, and practical management of clients in the workplace. Dysphagia is becoming an increasingly large part of the work done by Speech Language Pathologists. We wanted to provide a resource that helps to bridge the gaps between theoretical learning and hands-on practice and provide a resource that unpacks clinical reasoning and helps new clinicians think about how and why recommendations about managing clients with dysphagia are made. Click here for more details. For more books concerning Parkinson's Disease go to Parkinson's Disease Books.
12th January 2013 - New research PARKINSON'S DISEASE DOES NOT CAUSE COMPULSIONS Neurology [2013] 80 (2) : 176-180 (Weintraub D, Papay K, Siderowf A) Complete abstract Although compulsions can often occur in Parkinson's Disease, Parkinson's Disease does not actually cause compulsions or related problems. When people with Parkinson's Disease were compared with people who do not have Parkinson's Disease the frequencies of compulsions were little different : gambling (1.2% v 0.7%), buying (3% v 2%), sexual behaviour (4.2% v 3.5%), eating (7% v 10%), punding (prolonged, purposeless, and stereotyped behaviour) (5% v 2%), hobbyism (5% v 12%), walkabout (0.6% v 0.7%), any compulsions (18% v 20%). The fact that Parkinson's Disease itself does not seem to cause an increased risk of developing compulsions or related behaviour further reinforces the reported association between Parkinson's Disease drugs and causing compulsions. Given that approximately 20% of people with newly diagnosed Parkinson's Disease report some impulse control or related behaviour symptoms, long-term follow-up is needed to determine whether such people are at increased risk for impulse control disorder development once Parkinson's Disease drugs are initiated. For a printable version of this article click here. In order to refer to this article on its own click here.
11th January 2013 - News release SALIVA GLAND TEST FOR PARKINSON'S DISEASE New research has suggested that testing a portion of a person's saliva gland may be a means of diagnosing Parkinson's Disease. It was previously shown in autopsies of people with Parkinson's Disease patients that the abnormal proteins associated with Parkinson's are consistently found in the submandibular saliva glands, which are found under the lower jaw. The study involved 15 people with an average age of 68 who had Parkinson's disease for an average of 12 years, who responded to Parkinson's medication and who did not have known saliva gland disorders. Biopsies were taken of two different saliva glands. The abnormal Parkinson's protein was detected in nine of the 11 patients who had enough tissue to study. This is the first study demonstrating the value of testing a portion of the saliva gland to diagnose a living person with Parkinson's Disease. For more information go to the News release For a printable version of this article click here. In order to refer to this article on its own click here.
27th December 2012 - New research THE INCIDENCE OF PARKINSON'S DISEASE IS DECLINING
Journal of Neurology [2012] Dec 23 [Epub ahead of print] (Horsfall L, Petersen
I, Walters K, Schrag A.)
Complete abstract Although increasing population means that there are more people with Parkinson's Disease overall, this is the first time that the chances of developing Parkinson's Disease has been found to be continuously decreasing. The incidence of Parkinson's Disease in this study was found to be 46% higher in men than in women. The incidence rates were 12% higher in urban areas, and slightly less in socially deprived areas. For a printable version of this article click here. In order to refer to this article on its own click here.
26th December 2012 - New book THE GREAT COTZIAS : DISCOVERER OF THE TREATMENT FOR PARKINSON'S DISEASE Dr. Bernard Michael Patten (Author), Rita Mills (Author), Faye Walker (Editor) Publisher's description : Dr. Bernard Patten authentically captures in The Great Cotzias the realities of medical research; the petty jealousies, the back biting, the desperate race to knowledge. We get the details, of the events and the people involved in the discovery of the beneficial effect of L-DOPA on Parkinson’s disease. The main character is George C. Cotzias, a Greek born, Harvard educated, hypomanic physician who in his frenetic drive to win the Nobel Prize sacrificed wife, family, friends, and, finally himself. Eventually he makes the discovery that proved that so-called hopeless degenerative nervous system diseases can benefit from replacement of natural body chemicals that are deficient with the disease. Click here for more details. For more books concerning Parkinson's Disease go to Parkinson's Disease Books.
25th December 2012 - New book I FORGOT THAT I REMEMBERED Kevin T Boekhoff Publisher's description : "I Forgot That I Remembered" provides a glimpse into the day to day challenges of a person living with a chronic disease. Kevin relates the various struggles he deals with while living with Parkinson's. Those with a chronic illness can relate in many ways to his unwanted changes and adaptations. His unique writing style and humor may have you laughing, yet the reality in the stories may being tears. Each story relates different aspects of life with a chronic illness. They are arranged like the occur in life - random and unplanned. "...the very thing I struggle with every single day (Parkinson's disease); is the same thing that enables me to write - paradoxicity methinks." Click here for more details. For more books concerning Parkinson's Disease go to Parkinson's Disease Books.
15th December 2012 - New book ACUPRESSURE FOR PARKINSONISM MADE EASY Dr Krishna N.Sharma Publisher's description : Acupressure for Parkinsonism Made Easy - An Illustrated Self Treatment Guide is an unique book full of illustrations and written in very simple language. The coverage of the most of the Parkinsonism/ Parkinson's Disease complications make is equally useful for all the Parkinsonism patients regardless their type and stage of disease. Dr. Krishna N. Sharma is an Author, Medical Professional and Educator. He is founder Editor of the Scientific Research Journal of India and founder Gen. Secretary of the Online Physio Community, India. He writes health articles and columns in various newspapers and magazines of India and Bangladesh. So far he has written more than a dozen books. Click here for more details. For more books concerning Parkinson's Disease go to Parkinson's Disease Books
2nd December 2012 - New research GM1 GANGLIOSIDE CLINICAL TRIAL RESULTS Journal of the Neurological Sciences [2012] Nov 20 [Epub ahead of print] (J.S.Schneider, S.M.Gollomp, S.Sendek, A.Colcher, F.Cambi, Wei Du) Complete abstract A clinical trial was carried out to assess the symptomatic and disease-modifying effects of GM1 ganglioside in Parkinson's Disease. The authors do not know the precise mechanism of GM1 ganglioside but suggest what effects it has are "neuroprotective". Gangliosides are concentrated on cell surfaces mainly in the nervous system. They have been considered for use in neurological disorders. For more information go to Gangliosides. GM1 ganglioside was assessed for 120 weeks in people with Parkinson's Disease. The effects were compared to those people who delayed starting the treatment. At week 24, the early-start group had significant improvement in Parkinson's Disease motor symptoms. There was a significant worsening of scores in those people that delayed starting the treatment. At week 72 and week 120 those people taking GM1 ganglioside from the outset were better than those that did not. There was only a reduced worsening of symptoms after 120 weeks. So it was slowing deterioration rather than ridding symptoms. There were similar results in a previous study. For more information concerning the previous study go to the Complete abstract For a printable version of this article click here. In order to refer to this article on its own click here.
29th November 2012 - News release PIMAVANSERIN CLINICAL TRIAL RESULTS Arcadia have disclosed the results of their Phase III clinical trial of Pimavanserin, which is being developed by Arcadia for the treatment of Parkinson's Disease Psychosis. Parkinson's Disease Psychosis usually consists of visual hallucinations and delusions in addition to the usual Parkinson's Disease symptoms. Pimavanserin is an antagonist of serotonin 5-HT2A receptors. For more information go to Pimavanserin. In the clinical trial patients took either 40 mg of Pimavanserin or a placebo once a day for six weeks. Patients also received stable doses of their existing Parkinson’s Disease treatments throughout the study. Those people taking Pimavanserin reduced their score on the SAPS-PD scale by 5.79. Those people taking a placebo reduced their score by 2.73. Although the results were described as "representing a highly significant and clinically meaningful treatment" the effects of Pimavanserin were quite moderate when compared to those taking a placebo. Half the effect of Pimavanserin was achieved by effectively taking nothing at all. The study also fails to assess the long term effects of Pimavanserin as it lasted only 43 days. All drugs, due to a process called "feedback inhibition" end up reducing their over time. The most common adverse events were urinary tract infection and falls, but these were at a rate very little more than for those taking a placebo. Most symptoms of psychosis in Parkinson's Disease are due to Parkinson's Disease drugs themselves. For more information go to the News release. For a printable version of this article click here. In order to refer to this article on its own click here.
28th November 2012 - New book UNSHAKEN FAITH Machele Coleman Bess Publisher's description : When Machele Bess is diagnosed with Parkinsons disease her life becomes a little shaky. Coming from a Christian family, however, Machele has learned to have faith in God and continue to think positive. While Machele has been diagnosed with an uncommon disease, she strives to appreciate the little things in life and remember that He (God) alone is her fortress and she will not be shaken. Machele is not the only person who has to struggle with her disease, however. Her family was impacted by her daily struggles. Travel with Machele through her path to recovery in Unshaken Faith: a Parkinsons Pocketbook as she exposes her struggles, but enlightens those diagnosed with Parkinsons, or even those working to help a Parkinsons patient. Click here for more details. For more books concerning Parkinson's Disease go to Parkinson's Disease Books.
10th November 2012 - News release A FUTURE REPLACEMENT FOR SINEMET Depomed are developing a new drug called DM-1992 that could outperform Sinemet in the treatment of Parkinson's Disease. Just like Sinemet, DM-1992 is a combination of L-dopa and carbidopa, which prevents the breakdown of L-dopa. DM-1992 also includes AcuForm, which makes use of the properties of certain polymers. These polymers have long been used to "fluff" ice cream and are safe to use. Upon entering the stomach an AcuForm coated pill expands and is retained in the stomach for up to 8 hours. For more information go to Depomed. AcuForm helps to deliver a drug like Sinemet over a longer period of time. Depomed's formulation was able to extend the therapeutic duration of L-dopa to nine hours, compared to Sinemet CR's seven hours. The time to reach peak blood levels was extended to four hours compared to 2 hours for Sinemet CR. These advantages could enable a decrease in the dosage of L-dopa, and the ridding of side effects such as nausea and dyskinesia. In the most recent clinical trial, DM-1992 reduced off time from 5.4 hours per day to 4.5 hours per day. DM-1992 was generally well tolerated in the study, and there were no serious adverse events. For the news release click here. For a printable version of this article click here. In order to refer to this article on its own click here.
8th November 2012 - New book NAVIGATING LIFE WITH PARKINSON DISEASE Sotirios Parashos (Author), Rosemary Wichmann (Author), Todd Melby (Contributor) Publisher's description : Containing the most up-to-date information on the disease, it discusses the available treatments and provides practical advice on how to manage the disease in the long term. Emphasizing life-style adjustments that will provide a better quality of life and moderate the burden for patients and their loved ones, the book answers many questions and clarifies misunderstandings regarding the disease. The book is approachable and easily understandable. Question and answer sections are provided, while "hot topics" are highlighted for easy visibility. The authors have also included true patient stories that will both inspire and instruct, and they have addressed several topics often not mentioned in physician-directed disease management. Click here for more details. For more books concerning Parkinson's Disease go to Parkinson's Disease Books.
30th October 2012 - New research CIRRHOSIS CAN CAUSE PARKINSON'S DISEASE SYMPTOMS Metabolic Brain Disease [2012] Oct 20 [Epub ahead of print] (R.F. Butterworth) Complete abstract Acquired hepatolenticular degeneration is also known as "Parkinsonism in cirrhosis". Estimates of the prevalence of Parkinsonism in cirrhosis have been reported as high as more than 20 %. Cirrhosis is due to chronic liver disease. For more information go to Cirrhosis. The cause of Parkinsonism in cirrhosis has been attributed to manganese deposition in the basal ganglia, leading to dysfunction of the dopaminergic system. Blood and cerebrospinal fluid manganese concentrations were several times above the reference range. There is evidence of damage to, or dysfunction of, dopamine transporters and dopamine receptors. In many patients L-Dopa and dopamine agonists can be beneficial. Liver transplantation is usually effective. Parkinsonism in cirrhosis is characterized by symptoms including hypokinesia, dystonia and rigidity that are rapidly progressive. Typical features included rapid progression over months, symmetric akinetic-rigid syndrome, postural but not resting tremor, and early postural and gait impairment. Neuropsychiatric manifestations were minimal. For a printable version of this article click here. In order to refer to this article on its own click here.
24th October 2012 - New research ODM-101 FOUND TO BE MORE EFFECTIVE THAN STALEVO ODM-101, a new L-dopa product currently being developed by Orion for the treatment of Parkinson's disease, has successfully completed Phase II Proof of Concept trial. The key results indicate that ODM-101 was more effective than the reference product Stalevo in the treatment of advanced Parkinson's Disease. Stalevo is a standard drug for advanced Parkinson's patients experiencing end-of-dose wearing-off symptoms associated with L-dopa therapy. Stalevo is an enhanced L-dopa treatment containing three active substances in one tablet : L-dopa and the enzyme inhibitors entacapone and carbidopa. For more information go to Stalevo. Orion do not detail in which way ODM-101 and Stalevo are chemically different. The study included more than 100 patients in Europe. The Principal Investigator said "This phase II study demonstrated that ODM-101 has potential to be significantly more effective than Stalevo in the daily treatment of Parkinson's disease patients with response fluctuations. ODM-101 reduced time periods during the day when patients do not have adequate treatment response. These benefits were possible without an increase in troublesome involuntary movements (dyskinesia)." For more information, go to the News release. In order to refer to this article on its own click here.
23rd October 2012 - New web site THE PARKINSON HUB Theparkinsonhub is a new Parkinson's Disease web site that aims to provide patients, carers and healthcare professionals with the latest news, link and information in the area of Parkinson’s disease. "Whether you’re wondering ‘How do you get Parkinson’s ?’, need to know about what it’s like to start working with Parkinson’s or are wondering about what daily life will be like", they offer a range of resources for anyone who is in need of information. For more information, go to theparkinsonhub.
22nd October 2012 - New book PARKINSON'S DISEASE, SECOND EDITION Ronald F. Pfeiffer (Editor), Zbigniew K. Wszolek (Editor), Manuchair Ebadi (Editor) Publisher's description : In recent years, considerable advances have been made in our knowledge and understanding of Parkinson's disease (PD). In particular, there has been an explosion of information regarding genetic contributions to the etiology of PD and an increased awareness of the incidence and importance of the non-motor features of the disease. Theories regarding the pathogenesis and pathophysiology of PD have also been refined, and new treatment modalities and advances have been implemented. Reflecting these changes, this second edition features new chapters devoted to genetic aspects of PD, non-motor features of the disease, as well as aspects of the pathophysiology, pathogenesis, and treatment of PD. Click here for more details. For more books concerning Parkinson's Disease go to Parkinson's Disease Books.
13th October 2012 - New research SEASONAL EFFECT ON DOPAMINE Neuroscience Letters [2102] Oct 2 [Epub ahead of print] (Kaasinen V, Jokinen P, Joutsa J, Eskola O, Rinne JO) Complete abstract The formation of dopamine, the substance whose deficiency causes Parkinson's Disease, has been found to vary according to the season of the year, and the season in which somebody is born. This means that the likelihood of Parkinson's Disease symptoms are likely to change according to the season of the year, and in which season somebody was born The capacity to produce dopamine was found to be higher in people with Parkinson's Disease during the autumn (fall) and the winter. The potential was 15% higher during autumn (fall) and winter than it was during spring and summer. Dopamine levels were also affected by which season people were born in. People born during winter and spring were found to have a clearly higher capacity to produce dopamine compared to people born during the summer and autumn (fall). Therefore, the season in which somebody is born could cause Parkinson's Disease to be more or less likely. There was also evidence of season of birth effects in several neuropsychiatric disorders. For a printable version of this article click here. In order to refer to this article on its own click here.
27th September 2012 - New research THE CLINICAL FEATURES OF VASCULAR PARKINSONISM Journal of Neurology, Neurosurgery and Psychiatry [2012] 83 (10) : 1027-1029 (Glass PG, Lees AJ, Bacellar A, Zijlmans J, Katzenschlager R, Silveira-Moriyama L.) Complete abstract Vascular Parkinsonism is produced by strokes that affect the basal ganglia in the brain. A stroke is the loss of activity of a discreet area of the brain because of blockage of the blood supply to that brain region. Researchers evaluated in detail the clinical features in confirmed cases of Vascular Parkinsonism. Those assessed in the study had an average age of onset at 70 years old, and had Parkinson's Disease for an average of just over 10 years. Bradykinesia (slow movement) was present in everybody who had Vascular Parkinsonism. Rigidity was present in almost everybody (96% of cases). Falls were present in 76%, pyramidal signs in 54%, urinary incontinence in 50% and dementia in 39%. None of them had visual hallucinations. Two thirds of them developed Vascular Parkinsonism in a seemingly harmless way but actually with grave effects. The progression of the disability was then relentless. People with Vascular Parkinsonism had an older age of onset than those people who had Parkinson's Disease. This pattern of symptoms might help distinguish Vascular Parkinsonism from Parkinson's Disease. For a printable version of this article click here. In order to refer to this article on its own click here.
23rd July 2012 - New book FRONTIERS IN PARKINSON'S DISEASE RESEARCH Aderbal S. (Author, Editor), Jr. Aguiar (Author, Editor), Rui D. S. Prediger (Editor) Publisher's description : Parkinson's disease is a neurodegenerative disorder that affects approximately 1 million persons in the United States. This disease has been a force in the transformation of neurology from a specialty restricted to diagnosis into one with active and controversial therapies. This book is an up-to-date volume presenting hot topics in this actual scenario. Sections include new functional aspects of basal ganglia, little-known environmental factors in the aetiology of the disease, insights into the disease-related neurodegeneration, a critical discussion of current treatments and their limitations, and unexplored neuropsychiatric presentations of the disease. Click here for more details. For more books concerning Parkinson's Disease go to Parkinson's Disease Books.
13th September 2012 - New research HIGH PREVALENCE OF PARKINSON'S DISEASE IN CANADA Parkinsonism Related Disorders [2012] 18 (4) : 327-331 (Allyson Jones C, Wayne Martin WR, Wieler M, King-Jesso P, Voaklander DC.) Complete abstract The prevalence of Parkinson's Disease in Canada has been found to be one of the highest of any country in the world. The study was carried out in British Columbia, Canada. The prevalence rates amongst men were found to be 396-207 per 100,000 for men, and 259 to 127 per 100,000 for women. Combining the figures for both men and women gives figures of around 317 to 167 per 100,00. These figures are just below those of the U.S.A., which has one of the highest prevalence rates of any country. The only countries with higher prevalence rates than the U.S.A. and Canada are Albania and Egypt, where the prevalence rates are exceptionally high. The ratio of men to women with Parkinson's Disease in Canada is 1.56. As in most countries in the world, in Canada there are more men than women with Parkinson's Disease. For more concerning prevalence rates go to the Prevalence of Parkinson's Disease. For a printable version of this article click here. In order to refer to this article on its own click here.
9th September 2012 - New research THE SAFETY AND TOLERABILITY OF NEUPRO Parkinsonism Related Disorders [2012] Sep 3 [Epub ahead of print] (Oertel W, Lewitt P, Giladi N, Ghys L, Grieger F, Boroojerdi B.) Complete abstract Although dopamine agonists are sometimes perceived as poorly tolerated by the elderly, there is little clinical evidence to support these concerns. So the safety and tolerability of rotigotine transdermal system have been assessed in four 6-month studies. : two in early Parkinson's Disease and two in advanced Parkinson's Disease. Neupro® (Rotigotine Transdermal System) is a dopamine agonist that is applied to the skin in order to continuously deliver rotigotine over a 24-hour period. For more information go to Neupro. For most adverse events no age-related differences in were observed. In early Parkinson's Disease those symptoms more common in those younger than 65 in comparison to those who were 65 were : nausea (38% v 30%) and headache (15% v 9%). In another study, amongst older patients, those symptoms more common in those younger than 75 in comparison to those who were 75 were : nausea (36% v 21%), and dizziness (15% v 28%). In people with advanced Parkinson's Disease it was still the younger patients that more commonly had nausea (24% v 19%). It was only falls that were more common in older patients (13% v 8%). So oddly, the adverse events of this dopamine agonists were generally less rather than greater with age, as if the adverse events were adapted to. For a printable version of this article click here. In order to refer to this article on its own click here.
8th September 2012 - New research NFL PLAYERS TREBLE THE RISK OF PARKINSON'S DISEASE Neurology [2012] Sep 5 [Epub ahead of print] (Lehman EJ, Hein MJ, Baron SL, Gersic CM.) Complete abstract Players in the NFL ("American" Football's National Football League) were found to have treble the risk of haiving a neurodegenerative disease generally. This included Parkinson's Disease, Alzheimer's Disease and ALS. The figures for Alzheimer's Disease were more than three times more likely, and the figures for ALS were more than four times more likely. The likelihood of developing Parkinson's Disease was less than these. Although the research suggests that concussions and repeated blows to the head are likely to blame for the increased risk, the researcher says multiple studies are needed to definitively blame concussions. For a printable version of this article click here. In order to refer to this article on its own click here.
23rd August 2012 - New research THE PREVALENCE OF NON-MOTOR SYMPTOMS IN PARKINSON'S DISEASE
Clinical Neurology and Neurosurgery [2012] Aug 16
[Epub ahead of print] (E.M.Khedr, N.A.El Fetoh, H.Khalifa, M.A.Ahmed, K.M.El Beh)
Complete abstract The non-motor symptoms that were found to most prevalent in Parkinson's Disease were : disturbance of mood and cognition (87%), sleep disturbance and fatigue (78%), gastrointestinal (76%), urinary (76%), sexual dysfunction (73%), cardiovascular (70%). Perceptual problems and hallucinations are infrequent (10%) and are usually due to Parkinson's Disease drugs, especially dopamine agonists, rather than Parkinson's Disease itself. Dementia, which was found to be mostly mild, occurred in around 22% of people with Parkinson's Disease. Although dementia often eventually occurs in Parkinson's Disease, it has an entirely different biochemistry from Parkinson's Disease. It is therefore not actually a Parkinson's Disease symptom or inevitable in Parkinson's Disease. For a printable version of this article click here. In order to refer to this article on its own click here.
19th August 2012 - New research DIAGNOSIS OF PARKINSON'S DISEASE USING SPEECH
IEEE Transactions on Biomedical Engineering [2012]
59 (5) : 1264-1271 (A.Tsanas, M.A.Little, P.E.McSharry, J. Spielman, L.O.Ramig)
Complete abstract Researchers assessed how accurately such measures can be in discriminating people with Parkinson's Disease from people who do not have it. In total, the researchers computed 132 measures of dysphonia measures from sustained vowels. They then used a large database of vocal samples from different people. The researchers demonstrated that these measures of dysphonia can outperform standard methods of diagnosing Parkinson's Disease by reaching almost 99% overall classification accuracy. They achieved this by using only ten features of dysphonia. For a printable version of this article click here. In order to refer to this article on its own click here.
16th August 2012 - New research PARKINSON'S DISEASE IS PREVALENT AMONG NATIVE AMERICANS
Movement Disorders [2012] Aug 14 [Epub ahead of print] (P.H.Gordon, J.M.Mehal,
R.C.Holman, A.S.Rowland, J.E.Cheek)
Complete abstract The age adjusted prevalence of Parkinson's Disease was found to be 355 people per 100,000. This makes it the highest in North America, even beyond the 329 per 100,000 found in Nebraska, which was previously thought to have the highest prevalence of Parkinson's Disease in North America, and one of the highest in the world. The prevalence amongst Native Americans increased with age up until 84 years old, and was greater amongst men rather than women. For more concerning the prevalence of Parkinson's Disease go to the Prevalence of Parkinson's Disease. For a printable version of this article click here. For more news go to Parkinson's Disease News.
10th August 2012 - News report
BOB HOSKINS DIAGNOSED WITH PARKINSON'S DISEASE
8th August 2012 - New book PARKINSON'S HUMOR - FUNNY STORIES ABOUT MY LIFE WITH PARKINSON'S DISEASE Beverly Robaudo Publisher's description : I have Parkinson's Disease and a sense of humor! This is a collection of 100 funny stories about my life with Young Onset Parkinson's Disease. I also share some helpful advice for surviving this disease. Come learn and laugh with me! Laughter is the best medicine. Have a Happy Parkie Day ! Parkinson's Humor - Funny Stories about My Life with Parkinson's Disease has been published as a Kindle on Amazon. It is text to speech enabled. Click here for more details. For more books concerning Parkinson's Disease go to Parkinson's Disease Books.
2nd August 2012 - New research CAFFEINE REDUCES PARKINSON'S DISEASE Neurology [2012] Aug 1 [Epub ahead of print] (Postuma RB, Lang AE, Munhoz RP, Charland K, Pelletier A, Moscovich M, Filla L, Zanatta D, Romenets SR, Altman R, Chuang R, Shah B.) Complete abstract Neurology [2012] Aug 1 [Epub ahead of print] (Schwarzschild MA.) Complete abstract Caffeine was found to reduce Parkinson's Disease symptom scores using the standard scale for Parkinson's Disease, which is the UPDRS. There were no changes in quality of life, depression or sleep quality. The amount of coffee assessed was 2 to 4 cups of coffee per day. The trial lasted for 6 weeks. Caffeine is commonly found in coffee, and to a lesser extent in tea, cola drinks, cocoa, and chocolate. Studies had consistently linked caffeine, a non-selective adenosine antagonist, to a lower risk of Parkinson's Disease. However, the effects on the symptoms of people who already had Parkinson's Disease had not previously been adequately evaluated. The researcher described it as "a modest improvement, but may be enough to provide benefit to patients". He pointed out that the study was short and that the effects of caffeine may lessen over time. Previous studies that used much higher quantities (about 8 cups of coffee per day) resulted in no improvement in symptoms, and instead caused an increase in dyskinesia, restlessness and insomnia. For a printable version of this article click here. In order to refer to this article on its own click here.
26th July 2012 - News release SINGLE DRUG FOR PARKINSON'S, ALZHEIMER'S AND MULTIPLE SCLEROSIS A new class of drug is being developed at Northwestern University as a single therapy for Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis and traumatic brain injury by reducing inflammation in the brain. Northwestern University has been issued patents to cover this new drug class and has licensed the commercial development to a biotech company that has recently completed the first human Phase 1 clinical trial for the drug. The drugs in this class, represented by MW151 and MW189, target a particular type of brain inflammation, which they claim is a common denominator in these neurological disorders, as well as in traumatic brain injury and stroke. They claim that brain inflammation plays a major role in the progressive damage characteristic of these chronic diseases and brain injuries. For more information, go to the News release. Despite their claims, there is no evidence that inflammation is a primary cause of Parkinson's Disease. Parkinson's Disease has been shown to be due to the insufficient formation of dopamine, which is completely unaccounted for by this method. Their recent study solely concerned Alzheimer's Disease in mice who did not even have Alzheimer's Disease, and was not shown to rid or reduce Alzheimer's Disease. They have not obtained any evidence at all concerning efficacy in Parkinson's Disease. For a printable version of this article click here. In order to refer to this article on its own click here.
16th July 2012 - News release NEUPRO LAUNCHED IN THE U.S.A. TO TREAT PARKINSON'S DISEASE The role of UCB announced today that Neupro (Rotigotine Transdermal System) is now available in U.S. pharmacies. Neupro was approved by the U.S Food and Drug Administration in April to treat the signs and symptoms of early and advanced stage idiopathic Parkinson’s disease and moderate-to-severe primary Restless Legs Syndrome. Neupro is a once-daily patch that provides continuous delivery of the dopamine agonist rotigotine for 24 hours. Neupro is available in four different dosage strengths for the signs and symptoms of Parkinson’s disease (2 mg/24 hours, 4 mg/24 hours, 6 mg/24 hours, and 8 mg/24 hours). In clinical trials, the most common adverse reactions were nausea, vomiting, somnolence, application site reactions, dizziness, anorexia, insomnia, hyperhidrosis, peripheral edema, and dyskinesia. There is an increased risk for hallucinations in people with advanced-stage Parkinson’s Disease when they are treated with Neupro. Neupro may cause symptomatic postural/orthostatic hypotension and syncope (fainting), especially during dose escalation, elevated blood pressure, elevated heart rate, weight gain and fluid retention. Neupro should be used with caution in people with severe cardiovascular disease. Case reports suggest that patients can experience intense urges to gamble, increased sexual urges, intense urges to spend money, binge eating, and other intense urges, and the inability to control these urges while taking medications including Neupro. For more information, go to the News release. For a printable version of this article click here. In order to refer to this article on its own click here.
13th July 2012 - New research THE EFFECT OF PHYSIOTHERAPY ON PARKINSON'S DISEASE Cochrane Database Systematic Reviews [2012] 7 : CD002817 (Tomlinson CL, Patel S, Meek C, Clarke CE, Stowe R, Shah L, Sackley CM, Deane KH, Herd CP, Wheatley K, Ives N.) Complete abstract The role of physiotherapy in Parkinson's Disease aims to maximise functional ability and minimise secondary complications through movement rehabilitation. However, there are many methods of physiotherapy that have been used in Parkinson's Disease with differing effects. An analysis was carried out of all the published studies concerning the use of physiotherapy in Parkinson's Disease. Trials were classified into the following intervention comparisons : general physiotherapy, exercise, treadmill training, cueing, dance and martial arts. Physiotherapy was found to be beneficial using most methods in the short term (less than three months). The benefit was significant when using the following tests : velocity, step length, two-minute or six-minute walk tests, Timed Up & Go, Functional Reach Test, Berg Balance Scale and clinician-rated UPDRS. However, for some outcomes (velocity, Berg Balance Scale and UPDRS), the differences observed were at, or approaching, what are considered minimally clinical important changes. The review illustrates that a wide range of approaches are employed by physiotherapists to treat Parkinson's Disease. However, there was no evidence of very significant differences in treatment effect between the different types of physiotherapy used. For a printable version of this article click here. In order to refer to this article on its own click here.
8th July 2012 - New book RATING SCALES IN PARKINSON'S DISEASE : CLINICAL PRACTICE AND RESEARCH Cristina Sampaio, Christopher G.Goetz, Anette Schrag Publisher's description : For many years, the need to develop valid tools to evaluate signs and symptoms of Parkinson Disease has been present. Rating Scales in Parkinson's Disease: Clinical Practice and Research is written for researchers from the medical and social sciences, and for health professionals wishing to evaluate the progress of their patients suffering from Parkinson's Disease. The book is both exhaustive in the description of the scales and informative on the advantages and limitations of each scale. As such, the text clearly guides readers on how to choose and use the instruments available. Extensive cross-referenced tables and charts closely integrate the parts of the book to facilitate readers in moving from one symptom domain to another. Click here for more details. In order to refer to this article on its own click here. For more books concerning Parkinson's Disease go to Parkinson's Disease Books.
1st July 2012 - New research FIPAMEZOLE FOR DYSKINESIA IN PARKINSON'S DISEASE
Neurology 2012 Jun 27 [Epub ahead of print] (Lewitt PA, Hauser RA, Lu M,
Nicholas AP, Weiner W, Coppard N, Leinonen M, Savola JM.) Complete abstract The study was carried out in the U.S.A. and India. The total study population showed no statistically significant difference. However, because of the differences between the U.S. and Indian study populations, a prespecified subgroup analysis of U.S. subjects was conducted, showing fipamezole at 90 mg moderately reduced dyskinesia that was due to to L-dopa. The response was shown to be according to the dose used when assessing the different dosages (30mg, 60mg, and 90 mg fipamezole). Fipamezole induced mild and transient blood pressure elevation and was associated with what the authors describe as "an acceptable profile of adverse effects." For a printable version of this article click here. In order to refer to this article on its own click here.
26th June 2012 - News release LCIG CLINICAL TRIAL RESULTS FOR PARKINSON'S DISEASE Levodopa-carbidopa is administered in gel form, directly into the small intestine via a procedurally-implanted tube connected to a portable pump that delivers continuous supply of LCIG during waking hours. LCIG is currently approved in 40 countries. In the U.S.A., LCIG is an investigational therapy that is currently being evaluated in patients with advanced Parkinson's disease in additional Phase 3 clinical trials. Abbott have announced results from five abstracts evaluating levodopa-carbidopa intestinal gel (LCIG), concerning a 54 week open-label safety and tolerability study of people with advanced Parkinson's disease. The efficacy of LCIG was compared to that of standard levodopa-carbidopa immediate release, which is the same as Sinemet. There was nearly 2 hours less off time with LCIG. The most common adverse events were complication of device insertion (33%), abdominal pain (30%), procedural pain (21%) and nausea (16%). The most common serious adverse events were complication of device insertion (6%), abdominal pain (3%) peritonitis (3%) and polyneuropathy (3%). 7% of patients withdrew due to at least one adverse event. In another clinical trial the most common adverse events were complication of device insertion (51%), abdominal pain (42%), procedural pain (32%), nausea (25%), constipation (21%), orthostatic hypotension (18%), post-operative wound infection (17%), and incision site erythema (16%). For the full details go to the News release For a printable version of this article click here. In order to refer to this article on its own click here.
23rd June 2012 - New research SLEEP BENEFIT EXPERIENCED IN PARKINSON'S DISEASE
Journal of Parkinson's Disease [2012] DOI
10.3233/JPD-2012-12087 (Merrel van Gilst, Maartje Louter, Christian
Baumann, Bastiaan Bloem, Sebastiaan Overeem)
Complete study
20th June 2012 - New guidelines GUIDELINES ON PARKINSON'S DISEASE Parkinsons Society Canada have issued free guidelines concerning Parkinson's Disease. The Canadian Guidelines on Parkinson’s Disease will provide health care professionals with a detailed understanding of Parkinson’s Disease. The Guidelines are intended for a broad range of health professionals including: family physicians, neurologists, nurses, movement disorders specialists, allied health professionals (e.g. occupational therapists, physiotherapists, speech language pathologists) and other specialists. It is suggested that The Clinical Guidelines, published for the first time in 2012, will increase knowledge and will guide the diagnosis and treatment of Parkinson’s. For the guidelines go to Parkinsons Society Canada. For a printable version of this article click here. In order to refer to this article on its own click here.
16th June 2012 - New research ALCOHOL AND THE RISK OF PARKINSON'S DISEASE
Movement Disorders [2012] Jun 19 [Epub ahead of print] (Palacios N, Gao X,
O'Reilly E, Schwarzschild M, McCullough ML, Mayo T, Gapstur SM, Ascherio AA.)
Complete abstract
7th June 2012 - News release FIRST VACCINE FOR PARKINSON'S DISEASE The first clinical trial for the development of a Parkinson’s Disease vaccine has been started by AFFiRiS AG. The vaccine called PD01A is directed against alpha-Synuclein, a protein considered by AFFiRis to cause the onset and progression of Parkinson's Disease. The vaccination aims to educate the immune system to generate antibodies directed against alpha-Synuclein. They believe that a reduction of the brain’s alpha-Synuclein aggregates will have a beneficial impact on the progress of Parkinson's Disease. PD01A aims to accomplish that by the induction of antibodies that are targeting alpha-Synuclein, in order to neutralize its toxic impact. The vaccine is currently being tested on people with Parkinson’s Disease in a Phase I trial. The clinical trial is taking place in Vienna and involves up to 32 patients. The primary purpose is to assess the safety and tolerability of PD01A. For more information go to AFFiRis. The weakness in the theory on which the method is reliant is that a lot of people with Parkinson's Disease do not accumulate alpha-Synuclein. So there is none to get rid of. Most people that have an accumulation of alpha-Synuclein in the brain do not have Parkinson's Disease either, thereby proving that alpha-Synuclein is not the cause of Parkinson's Disease. For a printable version of this article click here. In order to refer to this article on its own click here.
4th June 2012 - New technology PARKINSON'S KINETIGRAPH The Parkinson's KinetiGraph has been devised to significantly improve the treatment available to people with Parkinson’s Disease by allowing accurate measurements of exactly how the Parkinson's Disease is affecting them. The Parkinson’s KinetiGraph system was commercialised by Global Kinetics Corporation. It consists of a sensor that is worn around the wrist of the patient to record data about their symptoms, and a computer unit which receives that data and analyses it. The device remotely records data about a person’s movement and via algorithms, provides a report for the their neurologist showing an objective measure of the presence and severity of bradykinesia and dyskinesia, the two key disabling symptoms of Parkinson’s Disease. The device also reminds the person when to take their Parkinson’s Disease drugs as prescribed by their medical practitioner. For more information go to Parkinson's KinetiGraph. For a printable version of this article click here. In order to refer to this article on its own click here.
|
||
|
|
||
.jpg) |
||
| ©2006-2007 Viartis | ||
| mail@viartis.net | ||